450 related articles for article (PubMed ID: 21936898)
1. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.
Lu H; Geng da Y; Shen F; Zhang JY; Lu B; Ma LX
Virol J; 2011 Sep; 8():444. PubMed ID: 21936898
[TBL] [Abstract][Full Text] [Related]
2. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
4. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
5. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
6. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
7. [The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B].
Xie DY; Lin BL; Xu QH; Chen YM; Lu WL; Li JG; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2008 May; 16(5):341-4. PubMed ID: 18510844
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
9. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
12. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
[TBL] [Abstract][Full Text] [Related]
13. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.
Minde Z; Yimin M; Guangbi Y; JinLin H; Hao W; Hong R; Yuming W; Xiaqiu Z; Daozhen X; Yagang C; Junqi N; Youming C; Yaozong W; Dixon J; Barker K
Liver Int; 2012 Jan; 32(1):137-46. PubMed ID: 22097972
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.
Gan W; Li J; Zhang C; Chen X; Lin C; Gao Z
BMC Infect Dis; 2020 Dec; 20(1):931. PubMed ID: 33287722
[TBL] [Abstract][Full Text] [Related]
15. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
Liang X; Cheng J; Sun Y; Chen X; Li T; Wang H; Jiang J; Chen X; Long H; Tang H; Yu Y; Sheng J; Chen S; Niu J; Ren H; Shi J; Dou X; Wan M; Jiang J; Xie Q; Shi G; Ning Q; Chen C; Tan D; Ma H; Sun J; Jia J; Zhuang H; Hou J
J Gastroenterol Hepatol; 2015 Apr; 30(4):748-55. PubMed ID: 25352300
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
Zeng M; Mao Y; Yao G; Wang H; Hou J; Wang Y; Ji BN; Chang CN; Barker KF
Hepatology; 2006 Jul; 44(1):108-16. PubMed ID: 16799983
[TBL] [Abstract][Full Text] [Related]
17. HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.
Tseng KC; Cheng PN; Wu IC; Chang CK; Chou AL; Liu WC; Chang TT
Hepatogastroenterology; 2009; 56(91-92):813-8. PubMed ID: 19621708
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P; Chang TT; Lim SG; Sievert W; Tong M; Arterburn S; Borroto-Esoda K; Frederick D; Rousseau F
Hepatology; 2008 Sep; 48(3):750-8. PubMed ID: 18752330
[TBL] [Abstract][Full Text] [Related]
19. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
20. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
